Former Director of Digital Clinical Trials at Bristol-Myers Squibb to advance corporate strategy, partnerships and growth for clinical trials platform provider
New York, New York (April 26, 2019) Inato, a platform for modern and inclusive clinical trials, announced the appointment of Liz Beatty as Chief Strategy Officer where she will advance Inato’s corporate strategy, continue to develop partnerships and drive growth in North America. Beatty spent 16 years at renowned pharmaceutical company Bristol-Myers Squibb where she most recently developed and led the digital clinical trials team within Global Clinical Operations before joining Inato.
“Liz is a decisive leader with unparalleled expertise in the digital clinical trials space and a clear track record of leveraging technology to increase clinical trial participation and enhance the clinical trial experience for sites and patients,” said Inato co-founder and CEO Kourosh Davarpanah. “She will play an important role in delivering on our mission to bring advanced technology, new doctors and their patients into the clinical research ecosystem to unlock the potential of the many unengaged research sites.”
“Inato has assembled some of the sharpest minds in digital healthcare and I am honored to join this exceptional team,” said Beatty. “The clinical research process is ripe for disruption and I’m excited to be part of a company that is fundamentally improving and accelerating the development of innovative treatments.”
Inato helps biopharmaceutical companies increase the pool of available patients engaged in clinical trials by discovering untapped research site potential. Inato’s platform matches the best sites for any given study and ensures that site partners in the Inato network are successfully delivering trials. The platform is built with doctors and for doctors—to navigate the increasingly complex research environment. Headquartered in Paris with offices in New York and London, Inato has raised $17 million in financing from Obvious Ventures, Cathay Innovation, Serena and Fly Ventures.